Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 685Carcinoma, Non-Small-Cell Lung 328Neoplasms 170Breast Neoplasms 166Lung Neoplasms 158Urinary Bladder Neoplasms 157Neoplasm Metastasis 140Cholangiocarcinoma 113Ovarian Neoplasms 106Biliary Tract Neoplasms 95Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 71Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 61Carcinoma, Transitional Cell 56Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Lymphoma, Non-Hodgkin 48Fallopian Tube Neoplasms 48Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

durvalumab 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumours × Gemcitabine × Clear all
NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

AstraZeneca

Phase 2 Active not recruiting
126 enrolled 30 charts
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡